Medulloblastoma
WNT, SHH, Group 3 and Group 4 disease, and relapse after craniospinal radiotherapy.
Each dot is one target. Higher means stronger genetic evidence in people (inherited variants or tumour mutations, whichever is stronger). Further right means more evidence from drugs already in trials or approved.
Scores run from 0 to 1 and are Open Targets' summary of how much evidence exists, not the chance a drug will work. The dividing lines sit at 0.5. Hover a dot for its numbers, click it for the target's page. Source: Open Targets Platform, fetched live.
The 25 targets in the top-left of the chart, strongest genetic evidence first. Click one for its drugs, tractability and other cancers.
All 50 targets, by type of evidence
Ranked by overall score for medulloblastoma on the Open Targets Platform. Darker cells mean stronger evidence of that type.
Peds RMTLmarks the 6 of these targets on the FDA's Pediatric Relevant Molecular Target List: a drug against one of them can be required to be studied in children under the RACE for Children Act.
| Target | Overall | Germline genetics | Somatic | genetic literature | Literature | Animal models | RNA expr. | Pathways | Clinical |
|---|---|---|---|---|---|---|---|---|---|
| SUFU SUFU negative regulator of hedgehog signaling | 0.80 | 0.93 | 0.66 | ||||||
| CTNNB1Peds RMTL catenin beta 1 | 0.75 | 0.71 | 0.85 | ||||||
| BRCA2 BRCA2 DNA repair associated | 0.74 | 0.94 | 0.23 | ||||||
| ELP1 elongator acetyltransferase complex subunit 1 | 0.72 | 0.91 | – | ||||||
| DDX3XPeds RMTL DEAD-box helicase 3 X-linked | 0.69 | – | 0.82 | ||||||
| PTCH1 patched 1 | 0.67 | 0.56 | 0.81 | ||||||
| KMT2D lysine methyltransferase 2D | 0.64 | – | 0.84 | ||||||
| GPR161 G protein-coupled receptor 161 | 0.64 | 0.75 | – | ||||||
| SMARCA4 SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4 | 0.62 | – | 0.74 | ||||||
| KMT2C lysine methyltransferase 2C | 0.59 | – | 0.78 | ||||||
| SMOPeds RMTL smoothened, frizzled class receptor | 0.59 | – | 0.73 | ||||||
| TP53Peds RMTL tumor protein p53 | 0.54 | – | 0.69 | ||||||
| ARID2 AT-rich interaction domain 2 | 0.49 | – | 0.65 | ||||||
| ARID1A AT-rich interaction domain 1A | 0.47 | – | 0.57 | ||||||
| NBN nibrin | 0.47 | – | – | ||||||
| GSR glutathione-disulfide reductase | 0.46 | – | – | ||||||
| KDM6A lysine demethylase 6A | 0.46 | – | 0.60 | ||||||
| MUTYH mutY DNA glycosylase | 0.46 | 0.75 | – | ||||||
| TUBB4A tubulin beta 4A class IVa | 0.44 | – | 0.19 | ||||||
| LDB1 LIM domain binding 1 | 0.44 | – | 0.73 | ||||||
| TUBA4A tubulin alpha 4a | 0.41 | – | – | ||||||
| TUBB3 tubulin beta 3 class III | 0.41 | – | – | ||||||
| TUBB tubulin beta class I | 0.41 | – | – | ||||||
| TUBB2B tubulin beta 2B class IIb | 0.41 | – | – | ||||||
| TUBB2A tubulin beta 2A class IIa | 0.41 | – | – | ||||||
| TUBA1B tubulin alpha 1b | 0.41 | – | – | ||||||
| TUBA3E tubulin alpha 3e | 0.41 | – | – | ||||||
| TUBA3C tubulin alpha 3c | 0.41 | – | – | ||||||
| TUBA1C tubulin alpha 1c | 0.41 | – | – | ||||||
| TUBB8 tubulin beta 8 class VIII | 0.41 | – | – | ||||||
| TUBB4B tubulin beta 4B class IVb | 0.41 | – | – | ||||||
| TUBA1A tubulin alpha 1a | 0.41 | – | – | ||||||
| TUBB1 tubulin beta 1 class VI | 0.41 | – | – | ||||||
| TUBB6 tubulin beta 6 class V | 0.41 | – | – | ||||||
| PRKAR1A protein kinase cAMP-dependent type I regulatory subunit alpha | 0.40 | – | 0.49 | ||||||
| PIK3CAPeds RMTL phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | 0.40 | – | 0.51 | ||||||
| CTCF CCCTC-binding factor | 0.40 | – | 0.52 | ||||||
| LRP1B LDL receptor related protein 1B | 0.40 | – | 0.52 | ||||||
| CSF3R colony stimulating factor 3 receptor | 0.40 | – | 0.30 | ||||||
| TOP2A DNA topoisomerase II alpha | 0.39 | – | – | ||||||
| CREBBP CREB binding lysine acetyltransferase | 0.39 | – | 0.51 | ||||||
| PTENPeds RMTL phosphatase and tensin homolog | 0.39 | – | 0.50 | ||||||
| TOP2B DNA topoisomerase II beta | 0.38 | – | – | ||||||
| DHFR dihydrofolate reductase | 0.38 | – | – | ||||||
| CACNA1D calcium voltage-gated channel subunit alpha1 D | 0.38 | – | 0.60 | ||||||
| ERBB4 erb-b2 receptor tyrosine kinase 4 | 0.37 | – | 0.57 | ||||||
| SF3B1 splicing factor 3b subunit 1 | 0.37 | – | 0.48 | ||||||
| ANK3 ankyrin 3 | 0.35 | – | 0.56 | ||||||
| APC APC regulator of Wnt signaling pathway | 0.35 | 0.41 | 0.43 | ||||||
| PRDM16 PR/SET domain 16 | 0.34 | – | 0.57 |
4 biomarkers in Medulloblastoma have validated or clinical evidence in CIViC
Accepted evidence from CIViC, the open (CC0) expert-curated knowledgebase, searched by the disease name “Medulloblastoma”. Level A is validated (for example in guidelines or an approval), level B comes from clinical trials or studies. 7 accepted items exist; the first 7 were read. This is the published evidence, not treatment advice.
- CTNNB1 Exon 3 Mutation level B
- PTCH1 LOH level B
- PTCH1 Mutation level B
- TP53 Mutation level B